WO2008033462A2 - Supple tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan - Google Patents
Supple tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan Download PDFInfo
- Publication number
- WO2008033462A2 WO2008033462A2 PCT/US2007/019927 US2007019927W WO2008033462A2 WO 2008033462 A2 WO2008033462 A2 WO 2008033462A2 US 2007019927 W US2007019927 W US 2007019927W WO 2008033462 A2 WO2008033462 A2 WO 2008033462A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- matrix
- supple
- chitosan
- freezing
- sponge structure
- Prior art date
Links
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 214
- 238000000034 method Methods 0.000 title claims abstract description 96
- 229920001477 hydrophilic polymer Polymers 0.000 title claims abstract description 45
- 230000000712 assembly Effects 0.000 title abstract description 22
- 238000000429 assembly Methods 0.000 title abstract description 22
- 239000002993 sponge (artificial) Substances 0.000 title abstract description 20
- 238000007710 freezing Methods 0.000 claims abstract description 105
- 230000008014 freezing Effects 0.000 claims abstract description 103
- 238000001816 cooling Methods 0.000 claims abstract description 49
- 238000001035 drying Methods 0.000 claims description 44
- 230000008569 process Effects 0.000 claims description 37
- 239000000463 material Substances 0.000 claims description 29
- 238000000859 sublimation Methods 0.000 claims description 24
- 230000008022 sublimation Effects 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 19
- 238000005191 phase separation Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 238000005096 rolling process Methods 0.000 claims description 6
- 238000005520 cutting process Methods 0.000 claims description 5
- 238000004781 supercooling Methods 0.000 claims description 5
- 238000007493 shaping process Methods 0.000 claims 4
- 238000004080 punching Methods 0.000 claims 2
- 238000005336 cracking Methods 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 239000011159 matrix material Substances 0.000 description 274
- 210000001519 tissue Anatomy 0.000 description 110
- 239000000243 solution Substances 0.000 description 77
- 208000027418 Wounds and injury Diseases 0.000 description 58
- 206010052428 Wound Diseases 0.000 description 49
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
- 239000012620 biological material Substances 0.000 description 36
- 238000000280 densification Methods 0.000 description 34
- 230000000740 bleeding effect Effects 0.000 description 29
- 208000032843 Hemorrhage Diseases 0.000 description 28
- 208000034158 bleeding Diseases 0.000 description 28
- 238000004108 freeze drying Methods 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- 238000004090 dissolution Methods 0.000 description 20
- 230000001954 sterilising effect Effects 0.000 description 18
- 238000004659 sterilization and disinfection Methods 0.000 description 18
- 241000446313 Lamella Species 0.000 description 17
- 230000001070 adhesive effect Effects 0.000 description 15
- 208000014674 injury Diseases 0.000 description 15
- 239000012071 phase Substances 0.000 description 15
- 238000001356 surgical procedure Methods 0.000 description 15
- 230000006911 nucleation Effects 0.000 description 14
- 238000010899 nucleation Methods 0.000 description 14
- 230000000845 anti-microbial effect Effects 0.000 description 13
- 230000000840 anti-viral effect Effects 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 239000000853 adhesive Substances 0.000 description 12
- 238000007906 compression Methods 0.000 description 12
- 230000006835 compression Effects 0.000 description 12
- 239000007789 gas Substances 0.000 description 12
- 230000004888 barrier function Effects 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 239000004599 antimicrobial Substances 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 206010053567 Coagulopathies Diseases 0.000 description 9
- 238000011067 equilibration Methods 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 210000000214 mouth Anatomy 0.000 description 8
- 208000031220 Hemophilia Diseases 0.000 description 7
- 208000009292 Hemophilia A Diseases 0.000 description 7
- 210000001124 body fluid Anatomy 0.000 description 7
- 239000010839 body fluid Substances 0.000 description 7
- 238000010792 warming Methods 0.000 description 7
- 229940121357 antivirals Drugs 0.000 description 6
- 208000015294 blood coagulation disease Diseases 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 5
- 206010067152 Oral herpes Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000009852 coagulant defect Effects 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 208000037816 tissue injury Diseases 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- 230000008733 trauma Effects 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 208000004898 Herpes Labialis Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000035602 clotting Effects 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 238000007872 degassing Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 210000003928 nasal cavity Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000003239 periodontal effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 206010060964 Arterial haemorrhage Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 206010065441 Venous haemorrhage Diseases 0.000 description 3
- 238000005452 bending Methods 0.000 description 3
- 239000000560 biocompatible material Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000002178 crystalline material Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 208000031169 hemorrhagic disease Diseases 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- 210000001847 jaw Anatomy 0.000 description 3
- 238000004898 kneading Methods 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000034693 Laceration Diseases 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 101000882917 Penaeus paulensis Hemolymph clottable protein Proteins 0.000 description 2
- 229920002413 Polyhexanide Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011344 liquid material Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000007769 metal material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 206010006797 Burns first degree Diseases 0.000 description 1
- 206010006802 Burns second degree Diseases 0.000 description 1
- 206010006803 Burns third degree Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010065173 Viral skin infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- -1 anion salts Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012945 sealing adhesive Substances 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 210000003781 tooth socket Anatomy 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00987—Apparatus or processes for manufacturing non-adhesive dressings or bandages
- A61F13/00991—Apparatus or processes for manufacturing non-adhesive dressings or bandages for treating webs, e.g. for moisturising, coating, impregnating or applying powder
- A61F13/00995—Apparatus or processes for manufacturing non-adhesive dressings or bandages for treating webs, e.g. for moisturising, coating, impregnating or applying powder for mechanical treatments
-
- A61F13/01034—
-
- A61F13/01038—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00157—Wound bandages for burns or skin transplants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/00463—Plasters use haemostatic
- A61F2013/00472—Plasters use haemostatic with chemical means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/00519—Plasters use for treating burn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00902—Plasters containing means
- A61F2013/00927—Plasters containing means with biological activity, e.g. enzymes for debriding wounds or others, collagen or growth factors
- A61F2013/00931—Plasters containing means with biological activity, e.g. enzymes for debriding wounds or others, collagen or growth factors chitin
Definitions
- the invention is generally directed to tissue dressing assemblies and systems applied on a site of tissue injury, or tissue trauma, or tissue access to ameliorate bleeding, fluid seepage or weeping, or other forms of fluid loss, as well as provide a protective covering over the site, as well as methods for manufacturing such tissue dressing assemblies and systems .
- HemCon ® Bandages made and sold by HemCon Medical Technologies Inc. (Portland, Oregon) incorporate a chitosan sponge matrix having superior adhesive properties and resistance to dissolution in high blood flow, which make them well suited for stanching of severe arterial blood flow.
- supple tissue dressing assemblies can be characterized by suppleness or multi -dimensional flexibility.
- the assemblies can be flexed, bent, folded, twisted, and even rolled upon itself before and during use, without creasing, cracking, fracturing, otherwise compromising the integrity and mechanical and/or therapeutic characteristics of the assemblies.
- the supple tissue dressing assemblies can be densified, if desired, to increase their adhesion and cohesion strengths, as well as impart increased dissolution resistance in the presence of larger volumes of blood and fluids.
- the supple tissue dressing assemblies can also be further softened by mechanical manipulation, if desired, which lends enhanced flexibility and compliance.
- the supple tissue dressing assembly comprises a biocompatible hydrophilic polymer form.
- the form is softened by a mechanical softening device comprising a plurality of spaced apart upper and lower rolling surfaces defining between them an undulating path sized and arranged to knead the form along an axis.
- Another aspect of the invention provides a method of making a sponge structure adapted for placement in contact with animal tissue.
- the method provides a biocompatible hydrophilic polymer solution.
- the method places the solution in a mold and places the mold in a freezer.
- the method uniformly cools the temperature of the solution, the mold, and the freezer from a first equilibrated temperature condition above freezing to a second temperature condition below freezing to impart a homogenous structure.
- the method dries the homogeneous structure in a durable form.
- Another aspect of the invention provides a method of forming making a sponge structure adapted for placement in contact with animal tissue.
- the method cools a biocompatible hydrophilic polymer solution,, to impart a structure in a frozen condition.
- the method dries the structure into a durable form by raising the temperature of the structure when in the frozen condition to a preselected sublimation temperature condition at which ice sublimates from the structure without collapsing the structure.
- the method maintains the preselected sublimation temperature condition until sublimation ceases.
- the method raises the preselected sublimation temperature condition to a drying temperature condition greater than the preselected sublimation temperature condition to remove residual moisture.
- tissue dressing assemblies can be used, e.g.,
- Fig. 2 is a perspective view of the supple tissue dressing assembly shown in Fig. 1, after having been rolled upon itself for use by a caregiver.
- Fig. 4 is a perspective view of the supple tissue dressing assembly shown in Fig. 4, being flexed in the hands of a caregiver.
- Figs. 5A and 5B are perspective views of representative molds in which a hydrophilic sponge material desirably comprising chitosan can be formed by- freezing and freeze-drying to form the supple tissue dressing assembly shown, respectively, in Fig. 1 and Fig. 3.
- Figs. 6A and 6B are perspective views of a measured volume of chitosan solution being placed into the molds shown in Figs. 5A and 5B prior to freezing.
- Fig. 7 is a perspective view of a freezer in which the chitosan solution, after having been placed into a molds as shown in Figs. 6A and 6B, is subjected to a prescribed freezing regime and subsequent freeze drying step.
- Figs. 8A and 8B are scanning electron microscope images (respectively at 30.0 kV x 30 and 30.0 kV X 100) of side sections of a desirable chitosan matrix (at room temperature without densification) that is formed as a result of the prescribed freezing regime and a subsequent freeze drying step within the freezer shown in Fig. 10, the freezing regime lowering the temperatures of the shelf, mold, chitosan solution, and air from room temperature to a freezing temperature at approximately the same rate (including a 30 minute freezing delay- interval at 5° C) to achieve a combined spherulitic and lamella nucleation of crystalline ice and subsequent phase separation that results in an inherently supple chitosan matrix structure.
- Fig. 9 is a graph showing the phases of proscribed freezing regimes, with and without a freezing delay- interval, that results in the creation of a desirable chitosan matrix structure of the type shown in Figs . 8A and 8B, and further comparing the freezing regimes, to a prior art freezing regime.
- Fig. 1OB is a graph depicting a representative embodiment of a prescribed drying process to sublimate ice from a chitosan structure of the type shown in Figs. 8A and 8B without meltback and collapse of the matrices.
- Figs. HA and HB are perspective views of the removal of a supple chitosan matrix structure from the molds shown in Figs. 6A and 6B after undergoing a freezing regime shown in Fig. 9 as well as a subsequent prescribed freeze-drying process shown in Fig. 10.
- Fig. 12 is a perspective view showing flexure of the supple, chitosan matrix structure after removal from the mold, as shown in Fig. HA.
- Figs. 13A, 13B, and 13C show the subsequent densification of the supple, chitosan matrix structure shown in Fig. 12, to create a supple, densified chitosan matrix structure.
- Fig. 14 is a perspective view of an oven which preconditions the supple, densified chitsan matrix structure shown in Fig. 13C.
- Fig. 15 is a perspective view of a softening machine, which subjects the supple, densified and preconditioned chitsan matrix structure (Figs. 13C and 14) to gentle, systematic mechanical softening along its longitudinal axis (length direction) , which improves its inherent suppleness and compliance.
- Fig. 17 is a more diagrammatic, side view of the array of upper and lower rollers shown in Fig. 16, with the supple, densified chitsan matrix structure traversing the serpentine path between the upper and lower rollers.
- Figs. 2OA, 20B, and 2OC are perspective views of an alternative embodiment of a softening tool that softens along the width direction of the matrix.
- Fig. 22 is a graph comparing the flexibility of a supple densified tissue dressing assembly to the flexibility of a state of the art tissue dressing matrix.
- Fig. 23 is a perspective view of a sealed pouch into which the supple tissue dressing assembly shown in roll form in Fig. 2 or the flat tissue dressing assembly shown in Fig. 3 is placed and sterilized prior to use by a caregiver.
- Fig. 26 is the segment of the supple tissue dressing assembly shown in Fig. 27 by shaped, pushed, and/or stuffed for topical application into a smaller wound track by a caregiver.
- Figs. 28A and 28B are perspective views of the pouch shown in Fig. 25 being opened by a caregiver to gain access to the supple tissue dressing assembly for use .
- Fig. 30 is a perspective view of a caregiver wrapping gauze about the supple tissue dressing assembly- shown in Fig. 11, after having been shaped, pushed, and/or stuffed into a wound track and pressure applied to stanch, seal, and/or stabilize a site of tissue injury.
- Figs. 1 and 2 show a representative embodiment of a supple tissue dressing assembly 10 that embodies features of the invention.
- the supple tissue dressing assembly 10 comprises a relatively thin and supple tissue dressing matrix 12 (shown Fig. 1) comprising a hydrophilic polymer that can be characterized as a supple sponge structure.
- the tissue dressing matrix 12 is formed by subjecting a solution of the hydrophilic polymer to a prescribed freezing regime followed by freeze drying (lyophilization) , which creates a unique dry supple sponge structure.
- freeze drying lyophilization
- Figs . 3 and 4 show another representative embodiment of a supple tissue dressing assembly 10' .
- the supple tissue dressing assembly 10' comprises a matrix 12' possessing the same unique supple sponge structure of the assembly 10 shown in Figs. 1 and 2, which is formed in generally the same manner by a prescribed freezing regime and freeze drying.
- the dry supple sponge structure forming the matrix 12' is not mechanically compressed and densified, and is therefore thicker (e.g., about 1 mm to about 8 mm thick) and less dense (e.g., a density of about .03 g/cm 3 , more or less) than the matrix 12 shown in Figs . 1 and 2.
- the present invention provides an efficient process for producing the tissue assembly 10 and 10' and the dressing matrix 12 and 12' .
- the hydrophilic polymer matrix 12 and 12' is created by subjecting a solution of the chitosan hydrophilic polymer to phase separation by a controlled freezing process, followed by a controlled water removal step by freeze- drying or lyophilization.
- the parameters of the freezing and lyophilization processes are controlled to create a dry supple sponge-like structure for the chitosan matrix 12 and 12'.
- Figs. 5A/5B to 12 a desirable methodology for making the matrix 12 or 12' will now be described.
- the process generally consists of the following steps:
- a chitosan solution which can, if desired, comprise a degassed solution
- the matrix 12 comprises poly [ ⁇ - (1 ⁇ 4) -2-amino-2-deoxy-D- glucopyranose , commonly- referred to as chitosan.
- the chitosan selected for the matrix 12 preferably has a weight average molecular weight of weight of greater than about 60 kDa, and at least about 100 kDa, and more preferably, of at least about 150 kDa. Most preferably, the chitosan has a weight average molecular weight of at least about 300 kDa.
- the chitosan used to prepare the chitosan solution preferably has a fractional degree of deacetylation greater than 0.78 but less than 0.97. Most preferably the chitosan has a fractional degree of deacetylation greater than 0.85 but less than 0.95.
- the chitosan selected for processing into the matrix has a viscosity at 25°C in a l%(w/w) solution of 1% (w/w) acetic acid (AA) with spindle LVI at 30 rpm, which is about 100 centipoise to about 2000 centipoise.
- the chitosan has viscosity at 25 0 C in a l%(w/w) solution of 1% (w/w) acetic acid (AA) with spindle LVI at 30 rpm, which is about 125 centipoise to about 1000 centipoise.
- the chitosan has viscosity at 25 0 C in a l%(w/w) solution of 1% (w/w) acetic acid (AA) with spindle LVl at 30 rpm, which is about 300 centipoise to about 850 centipoise.
- the chitosan is desirably placed into solution with an acid, such as glutamic acid, lactic acid, formic acid, hydrochloric acid, glycolic acid, and/or acetic acid.
- an acid such as glutamic acid, lactic acid, formic acid, hydrochloric acid, glycolic acid, and/or acetic acid.
- hydrochloric acid and acetic acid are most preferred, because chitosan acetate salt and chitosan chloride salt resist dissolution in blood whereas chitosan lactate salt and chitosan glutamate salt do not .
- Larger molecular weight (Mw) anions disrupt the para-crystalline structure of the chitosan salt, causing a plasticization effect in the structure (enhanced flexibility) . Undesirably, they also provide for rapid dissolution of these larger Mw anion salts in blood.
- the chitosan solution is preferably prepared at 25 0 C by addition of water to solid chitosan flake or powder and the solid dispersed in the liquid by agitation, stirring or shaking.
- the acid component is added and mixed through the dispersion to cause dissolution of the chitosan solid.
- the rate of dissolution will depend on the temperature of the solution, the molecular weight of the chitosan and the level of agitation.
- the dissolution step is performed within a closed tank reactor with agitating blades or a closed rotating vessel. This ensures homogeneous dissolution of the chitosan and no opportunity for high viscosity residue to be trapped on the side of the vessel.
- the chitosan solution percentage (w/w) is greater than 0.5% chitosan and less than 2.7% chitosan. More preferably the chitosan solution percentage (w/w) is greater than 1% chitosan and less than 2.3% chitosan. Most preferably the chitosan solution percentage is greater than 1.5% chitosan and less than 2.1% chitosan.
- the acid used is acetic acid.
- the acetic acid is added to the solution to provide for an acetic acid solution percentage (w/w) at more than 0.8% and less than 4%. More preferably the acetic acid is added to the solution to provide for an acetic acid solution percentage (w/w) at more than 1.5% (w/w) and less than 2.5%.
- certain gases can be added back into the solution to controlled partial pressures after initial degassing.
- gases would include but are not limited to argon, nitrogen and helium.
- An advantage of this step is that solutions containing partial pressures of these gases form micro-voids on freezing. The microvoid is then carried through the sponge as the ice- front advances. This leaves a well defined and controlled channel that aids sponge pore interconnectivity. 2. Molding the Chitosan
- the form producing steps for the chitosan matrix 12 and 12' are typically carried out from the solution.
- the form producing steps can he accomplished employing techniques such as freezing (to cause phase separation) , non-solvent die extrusion (to produce a filament) , electro-spinning (to produce a filament) , phase inversion and precipitation with a non- solvent (as is typically used to produce dialysis and filter membranes) or solution coating onto a preformed sponge- like or woven product .
- the chitosan biomaterial -- now in acid solution and (if desired) degassed, as described above -- is subjected to a form producing step that includes a controlled freezing process.
- the controlled freezing process is carried out by cooling the chitosan biomaterial solution within a mold 22 or 22' .
- the mold 22 or 22' can be variously constructed. As shown in Fig. 5A, the mold 22 for forming the elongated matrix 12 (Figs. 1 and 2) can be made from a metallic material, e.g., Mic 6 aluminum, although other metallic materials and alloys can be used, such as iron, nickel, silver, copper, titanium, titanium alloy, vanadium, molybdenum, gold, rhodium, palladium, platinum and/or combinations thereof.
- a metallic material e.g., Mic 6 aluminum
- other metallic materials and alloys can be used, such as iron, nickel, silver, copper, titanium, titanium alloy, vanadium, molybdenum, gold, rhodium, palladium, platinum and/or combinations thereof.
- the mold 22 measures overall 30 inches by 9.8 inches, and is compartmentalized into three mold chambers 24(1), 24(2), and 24(3), each 3 inches in width and 0.051 inch in depth.
- the mold chambers 24(1), 24(2), and 24(3) are desirably coated with a thin, permanently-bound, fluorinated release coating formed from polytetrafluoroethylene (Teflon) , fluorinated ethylene polymer (FEP) , or other fluorinated polymeric materials.
- Teflon polytetrafluoroethylene
- FEP fluorinated ethylene polymer
- the mold 22' for forming the smaller matrix 12' can be made from a plastic material compartmentalized into multiple small wells or chambers 24(1)' to 24 (n) ' for forming multiples of assemblies 10' at one time.
- a preselected volume of the chitosan biomaterial solution is conveyed from a source 26 into each mold chamber 24(1), 24(2), and 24(3) or 24(1)' to 24 (n) ' using, e.g., a positive displacement pump 28.
- a positive displacement pump 28 Given the mold dimensions disclosed above for creating the eleongated matrix 10 (Figs. 1 and 2), in a representative embodiment, 450 gr +/- 13 of chitosan biomaterial solution is conveyed into each mold chamber 24(1), 24(2), and 24(3). Adding a lesser volume of the chitosan biomaterial solution will result in a matrix that, after molding, possesses a thinner cross section and therefore an ultimately thinner finished matrix 12 and 12' .
- the mold 22 or 22' and chitosan biomaterial solution are then located on flat stainless-steel heating/cooling shelves 30 within a freeze dryer 32 (Fig. 16) .
- the flat base of each mold chamber 24(1), 24(2), and 24(3) or 24(1)' to 24 (n) ' is placed in close thermal contact with the flat stainless-steel heating/cooling surface of the shelf 30.
- a microprocessor controller 34 carries out the prescribed steps of the freezing process control algorithm.
- the freezing process can be carried out.
- the temperature of the chitosan biomaterial solution, the mold chambers 24(1), 24(2), or 24(3)- or 24(1)' to 24 (n) ' , and air within the freezer 32 is first equilibrated at a temperature above freezing.
- the equilibration temperature can be e.g., room temperature at or about 20° or 21° C.
- the equilibration temperature can be a higher temperature, or it can be lower temperature between freezing and room temperature, e.g., 5°C.
- Dispensing chitosan biomaterial solution into the mold chambers at a temperature above a freezing temperature makes possible the dispensing of the chitosan biomaterial solution in an efficient way.
- Allowing the mold chambers and the dispensed chitosan biomaterial solution to reach equilibrium at a temperature above freezing also allows the dispensed solution to reach a stable, level condition the mold chambers before freezing occurs. Also, because the equilibration temperature achieved within the freezer 32 is above freezing, frost accumulation does not become a problem.
- the temperature of the chitosan biomaterial solution, the mold chambers 24(1), 24(2), or 24(3) or 24(1)' to 24 (n) ' , and air within the freezer 32 is lower simultaneously from the initial equilibration temperature to a final temperature well below the freezing point (e.g., minus 40° C) .
- the chitosan biomaterial solution, each mold chamber 24(1), 24(2), and 24(3) or 24(1)' to 24 (n) ' , and the air within the freezer lose heat uniformly, causing uniform nucleation and, desirably, making the benefits of supercooling possible.
- the chitosan biomaterial solution undergoes homogenous phase separation and nucleation, to form the desired structure of the matrix.
- the temperatures of the shelf, mold, biomaterial solution, and surrounding air of the freezer are desirably lowered simultaneously at approximately the same rate or rates to achieve uniform nucleation during phase separation.
- the freezing rates can vary according to the desired physical properties desired.
- a representative cooling rate to achieve uniform nucleation is approximately about 1.0°C/min, but higher or lower cooling rates, such as rates below 0.5°C/min are possible and applicable.
- the cooling rate is a negative number, because the temperature is dropping from room temperature to a colder freezing temperature.
- the given cooling rates are approximates, as the cooling rate can and does typically change during the cooling process.
- a cooling rate of 1.0 °C/min is considered a greater negative rate and therefore not less than a cooling rate of 0.5°C/min.
- a cooling rate of 0.3 °C/min is considered a lesser negative rate and therefore is less than 0.5°C/min.
- the controller desirably commands a brief, rapid warming interval, during which time the below-freezing transition temperature is quickly raised (e.g., in less than 3 minutes) to a moderately elevated sub-freezing temperature (e.g., from minus 5°C to minus 3° C) . This is followed immediately by a resumption of the cooling interval from the elevated sub- freezing temperature to the final desired temperature (e.g., minus 40 0 C).
- the brief warming interval directly preceding the final cooling interval, subjects the chitosan biomaterial solution to super-cooling, for rapid nucleation and phase separation.
- the uniform cooling process produces a preferred structure for the chitosan matrix 12 of a type shown in Figs. 8A and 8B.
- This preferred structure is formed by a combined spherulitic and lamella nucleation of crystalline ice and its subsequent phase separation from the other solution components of acid and chitosan.
- Spherulitically nucleated structure both complements and modifies the normal lamella chitosan sponge structure.
- Spherulitic nucleation of ice is generally caused by uniformly cooling an aqueous solution to below its freezing point so that there is a uniform burst of ice crystals throughout the solution.
- the advantages of spherulitically nucleation type structures, once freeze dried, include (i) they are highly uniform,- (ii) they can have a large specific surface area; (iii) they resist cracking; and (iv) they have uniform strength.
- the resultant hybrid lamella and spherulitically nucleation type structures provide, after freeze drying, a matrix having improved crack resistance and dressing strength uniformity (i.e., suppleness) , while retaining sponge permeability.
- Figure 9 compares the uniform cooling process that begins at an equilibrium temperature above the freezing point with prior cooling methods.
- Freezing regime 100 and freezing regime 200 depict uniform cooling processes that begins at an equilibrium temperature above the freezing point, according to the present invention, while freezing regime 300 depicts a prior art process, wherein the shelf, mold, biomaterial solution, and air temperature are not cooled at approximately the same cooling rate from the same starting temperature.
- the freezing regime 100 implemented by the controller 34 includes lowering the chitosan biomaterial from the equilibration temperature (in this instance, at or near room temperature) to a final temperature below the freezing point and includes at least one intermediate delay interval 102 that holds a temperature condition for a prescribed period of time at a prescribed increment above the freezing point.
- the cooling process begins with the shelf, mold, biomaterial solution, and air temperature at the same temperature, approximately 20 "C.
- the room temperature is uniformly cooled at stage 106 over a time interval (e.g. 15 minutes) to a desired temperature (e.g.
- the temperature during the delay interval 102 is desirably between 2 0 C and 10° C, and the delay interval is between 20 and 40 minutes. As shown in Figure 9, the delay interval 102 takes place at a temperature of about 5°C for approximately 30 minutes.
- the delay interval 102 moderates the magnitude of the thermal gradient at the outset of phase separation, as nucleation begins and the spherulites form in the solution.
- the prescribed intermediate temperature and the duration of delay interval 102 result, at least for a portion of the delay- interval 102, in a thermal gradient that approaches zero.
- nucleation occurs more uniformly through the volume of chitosan biomaterial solution, allowing adjacent spherulites to form and connect and then open as lamella form, before the chitosan biomaterial solution is exposed to rapid freezing.
- a second cooling interval 108 which lasts for a desired time interval (e.g. 10 minutes) uniformly cools the freezer and the contents to a temperature below freezing (e.g. -5"C) , which allows for the chitosan material to change from a liquid to a crystalline material.
- a quick warming interval 110 then raises the temperature a few degrees (e.g. to -3 0 C), which is followed directly by a final cooling interval 112 to the final desired temperature (e.g. -4O 0 C).
- the warming interval 110 and the following cooling interval 112 allows the material to undergo a super-cooling process, which allows for the material to be converted from the original liquid material, to a crystalline material to a solid material, whereby water within the material is separated out of the material .
- freezing regime 200 provides a similar process to that of freezing regime 100, except that freezing regime 200 does not include a delay interval.
- the freezing regime 200 implemented by the controller 34 includes lowering the chitosan biomaterial from the initial equilibration temperature (e.g., room temperature) to a final temperature below the freezing point.
- the freezing regime 200 begins with the shelf, mold, biomaterial solution, and air temperature at the same temperature, approximately 20 1 C.
- the temperature is uniformly cooled at stage 206 over a time interval (e.g. 20 minutes) to a desired temperature (e.g. -5°C), with the contents of the freezer also being uniformly cooled to the same desired temperature at the same rate.
- a quick warming interval 210 then raises the temperature of the freezer a few degrees (e.g. to -3 1 C) , which is followed directly by a final cooling interval 212 to the final desired temperature (e.g. -40°C).
- the warming interval 210 and the following cooling interval 212 allows the material to undergo a super-cooling process, which allows for the material to be converted from the original liquid material, to a crystalline material to a solid material, whereby water within the material is separated out of the material .
- Figure 9 depicts a prior art freezing regime 300.
- the freezing regime begins at an initial stage 302, with the mold and biomaterial solution placed upon a shelf within the freezer, with the temperature of the freezer at approximately 15 'C.
- the initial temperatures of the chitosan material, molds, and freezer are not allowed to equilibrate and are therefore not uniform.
- a cooling stage 306 cools the freezer and the contents over a time interval (e.g. 60 minutes) to a final desired temperature (e.g. -4O 0 C). Freezing regime 300 is accomplished quicker than freezing regimes 100 and 200.
- freezing regime 300 results in a chitosan sponge structure that is more stiff and brittle, and therefore less able to accommodate extreme flexure without fracturing, as opposed to freezing regimes 100 and 200. 4. Freeze Drying the Chitosan/Ice Matrix
- the frozen chitosan/ice matrix desirably undergoes water removal (drying) from within the interstices of the frozen material.
- This water removal or drying step may be achieved without damaging the structural integrity of the frozen chitosan biomaterial.
- This may be achieved without producing a liquid phase, which can disrupt the structural arrangement of the ultimate chitosan matrix 12 and 12' .
- the ice in the frozen chitosan biomaterial passes from a solid frozen phase into a gas phase (sublimation) without the formation of an intermediate liquid phase.
- the sublimated gas is trapped as ice in an evacuated condenser chamber at substantially lower temperature than the frozen chitosan biomaterial .
- the spherulitically nucleated structures that are desirably present within the matrix 12 and 12' often retain considerable moisture due to an impermeable shell structure that forms around the ice core, conditions must be maintained during the water removal step to keep the matrix temperature below its collapse temperature, i.e., the temperature at which the ice core within the structure could melt before it is sublimated.
- the preferred manner of implementing the water removal step or drying is by freeze-drying, or lyophilization within the freezer 32. Freeze-drying of the frozen chitosan biomaterial can be conducted by further cooling the frozen chitosan biomaterial. Typically, a vacuum is then applied. Next, the evacuated frozen chitosan material is typically subject to ramped heating and/or cooling phases in the continued presence of a vacuum, as shown in Fig. 1OA. As shown in Fig.
- the drying phase 400 comprises a rapid rise of the shelf temperature up to the freezing point, which is maintained to allow sublimation of ice to occur (the primary drying step 402) , followed by a rapid rise of the shelf temperature to a higher drying temperature (e.g., 35° C), where secondary or residual drying of moisture occurs (the secondary drying step 404) .
- the final matrix from the freezing regimes 100 and 200 (Fig. 9) comprises a more homogenous and less open structure than matrices formed by from prior art regimes. Consequently, known drying processes such as shown in Fig. 1OA are not completely practical with currently- described freezing regimes, as they may not keep the matrix temperature below its collapse temperature, causing meltbacks and the collapse of the processed matrices .
- Fig. 1OB shows a drying process 500 specially suited for the more homogenous and less open structures from the freezing regimes 100 and 200.
- the controller senses temperature of the chamber molds as well as the temperature of the shelves within the freezer and governs the temperature conditions to carry out the drying process 500 in a primary phase 502, which causes sublimation of ice without meltback, and a secondary phase 504, which removes residual moisture.
- the drying process 500 results in an overall drying time that comparable to the process 400 shown in Fig. 1OA.
- the shelves of the freezer are rapidly heated to initiate rapid sublimation, while monitoring the temperature of the mold chambers .
- the meltback temperature a level slightly below the predetermined temperature (called the meltback temperature) at which the collapse of the processed matrices is predicted to occur (e.g., minus 8 0 C) (designated Point A in Fig. 10B)
- the shelves of the freezer are gradually cooled to maintain a substantially constant frozen chitosan biomaterial temperature in the mold chambers at a temperature below the meltback temperature.
- sublimation of ice to gas thereby occurs without collapse of the processed matrices .
- the temperature of the mold chambers continues to be monitored as the shelf temperature is reduced. This is because, as more of the ice is sublimated, there is less ice to sublimate, and rate of sublimation will diminish. The temperature of the mold chambers will therefore rise as the rate of sublimation diminishes. For this reason, as sublimation proceeds, the controller continues to command the gradual cooling of the shelf temperature, to keep the temperature of the mold chambers from approaching the meltback temperature.
- the temperature difference between the mold chambers and the shelves will decrease.
- the controller senses the state of the temperature difference, and switches the drying stage from primary to secondary when the temperature differences approaches or reaches zero.
- the secondary drying phase can begin at a temperature significantly above the meltback temperature, to remove residual moisture from the matrices.
- the drying process 500 shown in Fig. 1OB makes possible the drying of more homogenous and less open structures from the freezing regimes 100 and 200 in an overall drying time that comparable to the conventional process 400 shown in Fig. 1OA.
- the dry chitosan matrix 12 and 12' When removed from the mold chamber, the dry chitosan matrix 12 and 12' has a density at or near about .03 g/cm 3 as a result of the freezing regime 100 or 200. For purposes of description, this structure will be called an "uncompressed chitosan matrix.”
- the resultant matrix 12 and 12' can be further processed, if desired.
- either dry matrix 12 and 12' can be subject to further processing to impart other physical characteristics and otherwise optimize the matrix 12 and 12' for its intended end use.
- the supple uncompressed matrix 12' (shown ready for use in Figs. 3 and 4) has, after freezing and freeze-drying as described above, the requisite adhesion strength, cohesion strength, dissolution resistance, flexure, and conformity to perform well in such environments.
- the uncompressed dry matrix 12' can be removed from the mold, pouched, and sterilized without subsequent matrix processing steps.
- plastic mold trays can be sized and configured so that, after accommodating freezing and freeze-drying, each mold tray and the dry uncompressed matrix or matrixes it carries can be packaged as an integrated unit, thereby obviating removal of the dry matrix from the mold tray during packaging.
- the resulting plastic mold form package provides not only an aesthetic appearance, but also protects the dry matrix against product crushing during handling up to the instant of use.
- subsequent processing of the matrix may be warranted after drying and prior to packing and sterilization, for example, when the tissue dressing assembly 10 is intended to be, in use, exposed to higher volume blood flow or diffuse bleeding situations, or when exposure to relatively high volume of fluids is otherwise anticipated.
- Representative subsequent matrix processing steps will now be described after freezing and freeze- drying, to provide an assembly 10 of the type shown in Figs. 1 and 2.
- the matrix 12' of the type shown in Fig. 3 can be subject to one or more or all of these of these subsequent processing steps, if desired.
- the uncompressed dry- supple chitosan matrix 12 (Fig. 12) is desirably subject to a densification process.
- the densification process increases the density of the uncompressed dry chitosan matrix to a threshold density greater than or equal to 0.1 g/cm 3 , desirably between 0.1 g/cm 3 and about 0.5 g/cm3, and most desirably about 0.2 g/cm 3 . It has been observed that a chitosan matrix at or greater than the threshold density of about 0.1 g/cm 3 does not readily dissolve in flowing blood at 37°C.
- the chitosan matrix 12 can be characterized as a supple dry, densified chitosan matrix. It has been observed that the densification process imparts to the densified chitosan matrix 12 significantly increased adhesion strength, cohesion strength and dissolution resistance in the present of blood and liquids.
- the physical attributes of the densified dry chitosan matrix 12, in terms of the desired degree of suppleness and desired resistance to dissolution in flowing blood, can be expressed in terms of a ratio between the Gurley stiffness value of the dry matrix
- the densified chitosan matrix has a dry suppleness-to- density ratio ' value of not greater than about 50,000.
- a densified chitosan matrix having a dry suppleness-to-density ratio value of greater than about 50,000 either lacks the requisite resistance to dissolution in flowing blood, or the suppleness or multidimensional flexibility to be flexed, bent, folded, twisted, and even rolled upon itself before and during use, without creasing, cracking, fracturing, otherwise compromising the integrity and mechanical and/or therapeutic characteristics of the matrix 12, or a combination of both.
- the densified chitosan matrix has a dry suppleness-to-density ratio value of not greater than about 20,000, and most desirably not greater than about 10,000.
- a desirable representative range of dry suppleness-to-density ratio values is between about 4000 to about 20,000, and most desirably between about 2000 and about 10,000.
- Fig. 13A is placed inside a compression device 48. Inside the device 48, the uncompressed chitosan matrix 12 is compression loaded between heated platens 50 (Fig. 13B) .
- the compression device 48 may include one or more spacers of defined dimensions to ensure consistent thickness.
- the compression temperature is preferably not less than about 60 0 C, more preferably it is not less than about 75 0 C and not more than about 85 0 C.
- the compression load of the heated platens 50 reduces the thickness of the uncompressed dry matrix 12 from about 0.23 to 0.28 inches to about .036 inch (i.e., about 0.9 mm) .
- the compression load thereby increases the density of the uncompressed matrix from about .03 g/cm 3 to the target density of about 0.2 g/cm 3 .
- the supple dry densified chitosan matrix 12 (Fig. 21C) is formed, as is also shown in Fig. 1.
- the dry chitosan matrix - now densified -- is next preferably preconditioned by heating the densified supple chitosan matrix in an oven 70 (see Fig. 14) .
- the oven 70 can be operated at a temperature of preferably up to about 75 0 C, more preferably to a temperature of up to about 80 0 C, and most preferably to a temperature of preferably up to about 85 0 C.
- Preconditioning is typically- conducted for a period of time up to about 0.25 hours, preferably up to about 0.35 hours, more preferably up to about 0.45 hours, and most preferably up to about 0.50 hours. This pre-conditioning step provides further significant improvement in dissolution resistance with a small cost in a 20-30% loss of adhesion properties.
- the dry densified matrix 12 desirably has a Gurley stiffness value (in units of milligrams) (derived as previously discussed) of not greater than about 5000, preferably not greater than about 2500, and most desirably, at or about 1000.
- the densified chitosan matrix has a dry suppleness-to-density ratio value of not greater than about 50,000, preferably not greater than about 20,000, and most desirably not greater than about 10,000.
- a desirable range of dry suppleness- to-density ratio values is between about 4000 to about 20,000, and most desirably between about 2000 and about 10,000.
- the softening process can be accomplished by the use of certain plasticizing agents in solution with the chitosan.
- plasticizing may be problematic, because certain plasticizers can change other structural attributes of the assembly 10.
- the softening process is desirably- accomplished by the mechanical manipulation of the supple dry densified chitosan matrix.
- the mechanical manipulation can be accomplished in various ways.
- the supple dry densified chitosan matrix is passed through a softening device 52.
- the softening device 52 comprises an array of upper and lower rollers 54 and 56.
- the upper rollers 54 are longitudinally spaced apart along parallel axes.
- the lower rollers 56 are also spaced apart along parallel axes, which are also parallel to the axes of the upper rollers 54.
- the lower rollers 56 are further arranged in a staggered relationship relative to the upper rollers 54, such that each lower roller 56 is spaced below and between two spaced apart upper rollers 54 (see Fig. 17) , providing an undulating path between the upper and lower rollers 54 and 56.
- the distance between opposing upper and lower rollers 54 and 56 forming the path is slightly- less than the thickness of supple densified chitosan matrix.
- the supple densified chitosan matrix 12 is subject to compression or kneading as well as bending along its length axis on both sides of the matrix 12.
- a drive motor 58 (see Fig. 15) is linked by a suitable drive mechanism 60 to the rotate the rollers 54 and 56 (see Fig. 17) to draw the supple densified chitosan matrix 12 through one end of the path and discharge the supple densified chitosan matrix 12 from the opposite end of the path.
- the softening device 52 can further include a second softening array 62, arranged either before or after the first array of upper and lower rollers 54 and 56.
- the second softening array 62 is sized and arranged to compress or knead the supple densified chitosan matrix 12 along its witdth axis, i.e., along the width of the matrix 12 in a direction ninety degrees from the length compression or kneading provided by the first array of upper and lower rollers 54 and 56. In this arrangement (see Figs.
- the second softening array 62 can comprise an upper and lower array of wheels 64 and 66 arranged for rotation about an axis across the width of matrix 12.
- the upper wheels 64 are spaced apart along the upper axis
- the lower wheels 66 are spaced apart along the lower axis below and between the spaced apart upper wheels 64 (see Fig. 18) .
- the distance between two upper wheels 64 and an intermediate lower wheel 66 is slightly less than the thickness of supple densified chitosan matrix.
- a drive motor 68 and suitable drive linkage can be provided to draw the supple densified chitosan matrix 12 between the wheels 64 and 66 (see Fig. 19) .
- the supple densified chitosan matrix is subject to compression or kneading along its longitudinal axis.
- the matrix 12 can be softened in the width direction after it has been softened by the array of upper and lower rollers 54 and 56 by drawing the matrix width-wise through a tubular tool 70.
- the tubular tool 70 has a maximum interior diameter that is smaller than the width of the matrix 12.
- the maximum diameter of the tool 70 is 1 inch
- the matrix 12 is first drawn through the tube with the width curled up towards the crust side 72 (the side facing out of the mold) (Fig. 20B) , then drawn again with the width curled up towards the mold side 74 (the side facing the base of the mold)
- the softening device 52 as just described can be used to improve the flexibility and compliance of any hydrophilic polymer sponge structure after manufacture, without loss of beneficial features of robustness and longevity of resistance to dissolution. While the methodologies are described in the context of the supple densified chitosan matrix, it should be appreciated that the methodologies are broadly applicable for use with any form of hydrophilic polymer sponge structure, of which the supple densified chitosan matrix 12 is but one example .
- the densified, preconditioned, and softened chitosan matrix 12 exhibits all of the above-described characteristics deemed to be desirable for the dressing assembly 10. It also possesses the structural and mechanical benefits that lend robustness and longevity to the matrix during use.
- the densified, preconditioned, and softened chitosan matrix 12 makes it possible to readily bend and/or mold the assembly 10 prior to and during placement in or on a targeted injury site.
- the ability to bend and shape the assembly 10 is especially important when attempting to control strong or deep bleeding. Generally, such bleeding vessels are deep within irregularly shaped wounds. Apposition of the assembly 10 immediately against an injured vessel, and the ability to aggressively stuff the assembly into the wound, is beneficial in the control of such severe bleeding.
- the more supple and compliant the assembly 10 is the more resistant it is to tearing and fragmentation as the assembly 10 is made to conform to the shape of the wound and achieve apposition of the assembly 10 with the underlying irregular surface of the injury.
- Resistance to tearing and fragmentation is a benefit, as it maintains wound sealing and hemostatic efficacy.
- Compliance and flexibility provide an ability to load a chitosan matrix 12 (e.g., the assembly 10) against a deep or crevice shaped wound without cracking or significant dissolution of the assembly 10.
- the chitosan matrix 12 it may be desirable to mold the chitosan matrix 12 in the manner described, but in the smaller dressing sizes of the matrix 12', e.g., 4 inch by 4 inch, or 2 inch by 2 inch, or 2 inch by 4 inch, e.g., by using smaller mold cavities.
- the smaller dressing sizes can be created after molding by cutting an elongated molded matrix (as shown in Fig. 1) into smaller shaped pieces, either with or without densification and/or other preconditioning steps.
- the unique supple sponge structure of the dry chitosan matrix shown in Fig.
- the matrix 8A and 8B makes it possible to readily cut or shear the dry chitosan matrix by conventional cutting means (rotary shearing, scissors, knives, saws, or punch and die) into virtually any desired shape or size, without fracturing or splintering the matrix along the cut lines.
- the matrix can be cut when in an uncompressed form, with or without subsequent densification, or after densification, and/or preconditioning, and/or softening.
- a backing 14 to the dry chitosan matrix 12 , as shown in Fig. 21A.
- the backing 14 can, if desired, also be applied to an uncompressed chitosan matrix of the type shown in Fig. 3 prior to pouching and sterilization.
- the backing 14 can be attached or bonded by direct adhesion to a top or crust layer of a chitosan matrix 12 or 12' (i.e., the. layer that faces out of the mold) .
- an adhesive such as 3M 9942 Acrylate Skin Adhesive, or fibrin glue, or cyanoacrylate glue can he employed.
- the backing 14 isolates a caregiver's fingers and hand from the fluid-reactive chitosan matrix 12.
- the tissue dressing assembly 10 and 10' can he subsequently packaged by heat sealing in a pouch 16 (Fig. 23), as previously described, either in a rolled condition or a flattened condition (with or without a backing) .
- the pouch 16 may be purged, if desired, with an inert gas such as either argon or nitrogen gas. It may also be evacuated, if desired.
- the pouch 16 acts to maintain interior contents sterility over an extend time (at least 24 months) and also provides a very high barrier to moisture and atmospheric gas infiltration over the same period.
- the tissue dressing assembly 10 and 10' is desirably subjected to a sterilization step.
- the tissue dressing assembly 10 can be sterilized by a number of methods.
- a preferred method is by irradiation, such as by gamma irradiation, which can further enhance the blood dissolution resistance, the tensile properties and the adhesion properties of the wound dressing.
- the irradiation can be conducted at a level of at least about 5 kGy, more preferably a least about 10 kGy, and most preferably at least about 15 to 19 kGy.
- Another dry dressing assembly (Matrix 2: 455g weight of chitosan solution placed in the mold prior to freezing and freeze drying/and having a 0.9mm thickness after densification) was manufactured from the same chitosan solution using a freezing regime that placed the chitosan solution at room temperature into a mold that was placed on -40° C shelf without an intermediate delay interval, and then subsequently freeze dried to remove water without collapse of the matrix, and then subsequently densified and preconditioned (without softening) .
- Matrix 1 nor Matrix 2 were subjected to gamma sterilization prior to testing.
- test piece was a bar 1.27 cm wide (0.5") and 6.99 cm long (2.75"). Duct tape was placed on the top and bottom 1.9 cm (0.75") to avoid damaging the test piece ends when gripping and to ensure failure wass always in the middle test region (3.18 cm or 1.25") .
- Example 2 the test results of Example 2 demonstrate that, although the thickness and density for the dry Matrix 1 and dry Matrix 2 are the -same, the tensile orientations strengths of dry Matrix 1 and dry Matrix 2 after sterilization are also very different.
- the Matrix 1 and Matrix 2 tensile strengths (after sterilization) are, respectively 12.3 and 8.1 (Horizontal) and 12.4 and 5.4 (Vertical).
- the test results demonstrate a significant tensile advantage (both horizontally and vertically) (after sterilization) in Matrix 1. Further, the coefficient of variation in tensile strength for Matrix 1 remains near 30% both horizontally and vertically, which, like Example 1, demonstrates the remarkable uniformity of the construct.
- the adhesive characteristics of a tissue dressing assembly comprising a Matrix 1 (as above described) were tested and verified using a test fixture specially- designed for the task, as described in copending United States Patent Application Serial No. 11/020,365, filed December 23, 2004, which is incorporated herein by- reference.
- the test fixture provides a platform that simulates an arterial wound sealing environment.
- the test fixture makes it possible to assess, for that environment and exposure period, the burst (or rupture) strength of a given hydrophilic polymer sponge structure, or a manufactured lot of such structures, in a reproducible and statistically valid way that statistically correlates with in vivo use.
- the highest pressure state (burst strength, expressed in mmHg) observed is compared to a prescribed "pass-fail" criteria.
- Examples 1 and 2 demonstrate a coefficient of variation in tensile strength for Matrix 1 that indicates uniformity of structure among lots of Matrix 1 structures.
- This Example 4 further demonstrates a low standard of deviation of burst strengths among lots of Matrix 1 structures ( ⁇ 10%) , further indicating the overall uniformity in structure that is achieved with Matrix 1 structures.
- the HemCon ® Bandage includes a chitosan matrix that is formed by a freezing, lyophilization, densification and pretreatment process, but does not includes a delay interval in the freezing process or a softening step, as described above .
- Fig. 22 demonstrates the significantly improved flexibility of a Matrix 1 structure, both along its width (W) and along its length (L) , compared to the state of the art HemCon ® Bandage .
- Example 5 Based upon the tensile strength data obtained in Example 2 (after sterilization) and the flexural test data obtained in this Example 5, it can be seen that the densified material of dry Matrix 1 possesses a dry suppleness-to-strength ratio of about 208 (width direction) and about 83 (length direction) . In contrast, the state of the art HemCon ® Bandage possesses a dry suppleness-to-strength ratio value of about 453.
- the densified material of dry Matrix 1 (having a density about 0.2 g/ctn 3 ) possesses a dry suppleness-to-density ratio value of about 12,500 (width direction) and about 5000 (length direction) .
- the state of the art HemCon ® Bandage possesses a dry suppleness-to-density ratio value of about 170,000.
- the unique underlying dry sponge structure that comprises both tissue dressing matrixes 12 and 12' is characterized by its suppleness or multi-dimensional flexibility. Before densification (as Fig. 4 shows) or after densification (as Fig. 2 shows) , the dry matrix 12 and 12' can be flexed, bent, folded, twisted, and even rolled upon itself before and during use, without creasing, cracking, fracturing, otherwise compromising the integrity and mechanical and/or therapeutic characteristics of the matrix 12 and 12' .
- the unique underlying dry sponge structure that comprises both tissue dressing matrixes 12 and 12' can also be characterized by a suppleness or multi-dimensional flexibility in terms of a Gurley stiffness value (in units of milligrams) (when dry) of not greater than about 5000 (using a Gurley Stiffness Tester Model 4171D manufactured by Gurley Precision Instruments of Troy, New York, and Gurley ASTM D6125-97) .
- a dry sponge structure having a Gurley stiffness value (in units of milligrams) greater than about 5000 do not possess the requisite suppleness or multi-dimensional flexibility to be flexed, bent, folded, twisted, and even rolled upon itself before and during use, without creasing, cracking, fracturing, otherwise compromising the integrity and mechanical and/or therapeutic characteristics of the matrix 12 and 12' .
- the unique underlying dry sponge structure that comprises both tissue dressing matrixes 12 and 12' is characterized by a suppleness or multi -dimensional flexibility in terms of a Gurley stiffness value (in units of milligrams) (when dry) of not greater than about 2500, and most desirably, at or about 1000.
- the underlying dry sponge structure that comprises both tissue dressing matrixes 12 and 12' can also be characterized when dry by the unique combination of a clinically effective tensile strength (integrity) with the suppleness as previously described.
- This unique combination of physical attributes that the underlying dry sponge structure of the matrix 12 or 12' provides can be expressed in terms of a ratio between the Gurley stiffness value (in units of milligrams) (as determined when dry by using a Gurley Stiffness Tester Model 4171D manufactured by Gurley Precision Instruments of Troy, New York, and Gurley ASTM D6125-97) and tensile strength (expressed in units of Newtons) (as determined when dry- by an InstronTM Device and ASTM Test Method D412 (Method A, Section 12) ).
- the matrix 12 and 12' can provide a dry suppleness-to-strength ratio value of not greater than about 210, which makes possible a relatively high clinically useful tensile strength (e.g., 10 Newtons) with a supple structure having relatively low Gurley stiffness value (e.g., 2000 Gurley Units), particularly when the matrix 12 is used in densified form.
- the dry supple tissue dressing assembly 10 can be readily sized and configured to be unwrapped from a roll form, and then shaped, pushed, and/or stuffed into a wound track.
- the dry- tissue dressing matrix 12 can be readily cut or torn into smaller segments (Fig. 25) for topical application upon or insertion within a smaller wound (Fig. 26) .
- a segment of the dry tissue dressing matrix 12 can be readily folded into a "C" shape or another configuration to facilitate its insertion into a wound track.
- the densification of the dry matrix 12 imparts increased dissolution resistance in the presence of larger volumes of blood and fluids.
- the dry supple tissue dressing assembly 10' can be sized and configured with smaller, preformed dimensions for topical application for, e.g., low bleeding hemostasis and/or antibacterial/antiviral wound dressing applications.
- a densified matrix 12 can also be used for such applications, too.
- the dry tissue dressing matrix 12' can be cut or torn as desired into even smaller segments or into different shapes to conform to the topology of the application site.
- the hydrophilic polymer is exposed both sides of the dry supple tissue dressing matrix 12 and 12' .
- the hydrophilic polymer is elected to comprise a material that adheres to tissue in the presence of blood, or body- fluids, or moisture.
- the supple tissue dressing assembly 10 or 10' can thus be used to stanch, seal, and/or stabilize a site of tissue injury, or tissue trauma, or tissue access (e.g., a catheter or feeding tube) against bleeding, fluid seepage or weeping, or other forms of fluid loss.
- the tissue site treated can comprise, e.g., arterial and/or venous bleeding, or a laceration, or an entrance/entry wound, or a tissue puncture, or a catheter access site, or a burn, or a suture, or an open tooth socket.
- the supple tissue dressing assembly 10 can also desirably form an anti-bacterial and/or anti-microbial and/or anti-viral protective barrier at or surrounding the tissue treatment site.
- the supple tissue dressing matrix 12 and 12' can, of course, vary according to its intended use. As will be described in greater detail later, the supple tissue dressing matrix 12 and 12' is shaped by a mold during manufacture, either into the elongated and rectilinear form shown in Fig. 1 or in the smaller form shown in Fig. 3.
- the elongated tissue dressing matrix 12 can be formed, with mechanical compression and densification, with an overall length of about 28 inches (711 mm) , a width of about 3 inches (76 mm) , and a thickness of about 0.35 inch (0.9 mm), more or less.
- the thickness of a densified matrix 12 can range from about 0.25 mm to about 4 mm.
- the elongated tissue dressing matrix 12 has the flexibility to be bent, flexed, twisted or rolled upon itself, without creasing, cracking, or fracture. As shown in Fig.
- elongated tissue dressing matrix 12 can be manually rolled -tightly upon- itself , to form a roll that can be as small as about 1.5 inches (38 mm) in diameter, depending upon how tightly rolled the matrix is. Due to its suppleness, the initial elongated form of the tissue dressing matrix 12 can be rolled upon itself without fracture into the roll form shown in Fig. 2, which has a diameter that less than either the width or the length of the initial elongated form.
- the matrix 12' can be formed, without compression or densification, with smaller dimension, e.g., 2 inches (51 mm) by 2 inches (51 mm) by 0.16 inch (4 mm) or even smaller (e.g., for dental applications), e.g., 10mm x 12mm and about 4 mm thick, more or less.
- the thickness for an undensified matrix 12' can range between about 1 mm to 8 mm.
- the smaller tissue dressing matrix 12' also has the flexibility to be bent, flexed, twisted or rolled upon itself, without creasing, cracking, or fracture .
- assembly 10 can be further altered after manufacture by cutting, bending, molding, folding, or twisting either during use or in advance of use .
- the biocompatible material selected for the matrix 12 and 12' desirably reacts in the presence of blood, body fluid, or moisture to become a strong adhesive or glue.
- the selected biocompatible material also possesses other beneficial attributes, for example, antibacterial and/or anti -microbial anti -viral characteristics, and/or characteristics that accelerate or otherwise enhance the body's defensive reaction to injury.
- the tissue dressing matrix 12 and 12' may comprise a hydrophilic polymer form, such as a polyacrylate, an alginate, chitosan, a hydrophilic polyamine, a chitosan derivative, polylysine, polyethylene imine, xanthan, carrageenan, quaternary ammonium polymer, chondroitin sulfate, a starch, a modified cellulosic polymer, a dextran, hyaluronan or combinations thereof.
- the starch may be of amylase, amylopectin and a combination of amylopectin and amylase.
- the biocompatible material of the matrix 12 and 12' preferably comprises the non-mammalian material poly [ ⁇ - (1 ⁇ 4) -2-amino-2-deoxy-D- glucopyranose , which is more commonly referred to as chitosan.
- the chitosan matrix 12 and 12' presents a robust, permeable, high specific, positively charged surface.
- the positively charged surface creates a highly reactive surface for red blood cell and platelet interaction.
- Red blood cell membranes are negatively charged, and they are attracted to the chitosan matrix 12 and 12' .
- the cellular membranes fuse to chitosan matrix 12 and 12' upon contact.
- a clot can be formed very quickly, circumventing immediate need for clotting proteins that are normally- required for hemostasis.
- the chitosan matrix 12 and 12' is effective for both normal as well as anti -coagulated individuals, and as well as persons having a coagulation disorder like hemophilia.
- the chitosan matrix 12 and 12' also binds bacteria, endotoxins, and microbes, and can kill bacteria, microbes, and/or viral agents on contact.
- the hydrophilic polymer matrix 12 and 12' is created according to the previously described process, resulting in a dry supple sponge-like structure for the chitosan matrix 12 and 12' .
- the dry chitosan matrix 12 and 12' Due to its inherent suppleness, the dry chitosan matrix 12 and 12' is not stiff or brittle. It possesses an inherent capability for flexure and/or twisting without compromising its structural integrity and mechanical and therapeutic properties.
- the inherent suppleness of dry chitosan matrix 12 and 12' can also be further enhanced by a mechanical softening process.
- the density of the particular dry chitosan structure of the matrix 12 following freezing and freeze drying can be increased by the previously- described mechanical densification process.
- the mechanical densification process imparts enhanced adhesion strength, cohesion strength and dissolution resistance of the matrix 12 in the presence of blood or body fluids.
- Fig. 23 shows, before use, the tissue dressing assembly 10 and 10' is desirably packaged in roll form with low moisture content, preferably 5% moisture or less, in an air-tight heat sealed foil -lined pouch 16.
- the tissue dressing assembly 10 and 10' is subsequently terminally sterilized within the pouch 16 by use of gamma irradiation.
- the pouch 16 is configured to be peeled opened by the caregiver (see Figs. 28A and 28B) at the instant of use.
- the pouch 16 provides peel away access to the tissue dressing assembly 10 and 10' along one end (the roll-form densified tissue dressing assembly 10 is shown in Fig. 28B for purposes of illustration) .
- the opposing edges of the pouch 16 are grasped and pulled apart (Fig. 28A) to expose the tissue dressing pad assembly 10 and 10' for use.
- the tissue dressing assembly 10 and 10' is immediately ready to be adhered to the targeted tissue site. It needs no pre-application manipulation to promote adherence. For example, there is no need to peel away a protective material to expose an adhesive surface for use. The adhesive surface forms in situ, because the chitosan matrix 12 and 12' itself exhibits strong adhesive properties once in contact with blood, fluid, or moisture .
- the tissue dressing assembly 10 and 10' is applied to the injury site immediately upon opening the pouch 16.
- Fig. 24 shows the densified assembly 10 being applied for treating an arterial and/or venous bleeding injury.
- the chitosan matrix 12 is active on both sides of the assembly 10.
- the entire assembly 10 will become sticky when it is placed into contact with blood.
- the assembly 10 is handled quickly and pushed aggressively into the wound track (as Fig. 24 shows) .
- the assembly 10 is desirably placed directly on the source of bleeding, i.e., the area where the blood vessel damage has actually occurred. Desirably, once applied, the assembly 10 is not re-positioned.
- the assembly 10 With the densified assembly 10 inserted in the wound track (see Fig. 29) , the assembly 10 can be backed with KerlixTM roll or gauze 18, and pressure applied to the wound. Desirably, pressure is applied on the assembly 10 for at least two minutes, or until the assembly 10 adheres and the blood is controlled. Firm pressure is applied, to allow the natural adhesive activity of the chitosan matrix 12 to develop. The adhesive strength of the chitosan matrix 12 will increase with duration of applied pressure, up to about five minutes. Pressure applied evenly across the assembly 10 during this time will provide more uniform adhesion and wound sealing.
- a second conventional dressing 20 e.g., gauze
- a water tight covering should be applied to prevent the dressing assembly 10 from becoming over-hydrated.
- two or more densified dressing assemblies 10(1) and 10(2) can be applied side-by- side, if needed, to occupy the wound or tissue site.
- the chitosan matrix 12 of one assembly 10 will adhere to the chitosan matrix 12 of an adjacent assembly 10.
- the smaller, uncompressed dressing assembly 10' shown in Figs. 3 and 4 can also be appropriately applied to an intended dressing site. It, too, will become sticky when it is placed into contact with blood or body fluids, and will adhere as pressure is applied. When good dressing adhesion and coverage of the dressing .site are achieved, a second conventional dressing (e.g., gauze) can be applied to secure the dressing 10' and to provide a clean barrier for the wound.
- a second conventional dressing e.g., gauze
- the assembly 10 (or assembly 10') can also be torn or cut on site to match the size of the wound or tissue site. Smaller, patch pieces of an assembly 10 or 10' can also be cut to size on site, and fitted and adhered to the periphery of another assembly 10 or 10' to best approximate the topology and morphology of the treatment site.
- the supple assembly 10 or 10' accommodates layering, compaction, and/or rolling -- i.e., "stuffing" (as Fig. 5 shows for the densified assembly 10) -- of the chitosan matrix 12 (or matrix 12' ) within a wound site using pressure to further reinforce the overall structure against strong arterial and venous bleeding.
- stuffing the supple densified assembly 10 over itself as Fig. 5 shows, the interaction of the blood with the chitosan provides advantages for the application when the wounds are particularly deep or otherwise apparently inaccessible.
- the stuffing of the supple assembly 10 into a bleeding wound and its compression on itself provide for a highly adhesive, insoluble and highly conforming bandage form.
- the assembly 10 and 10' is intended to temporarily control severe bleeding.
- the assembly 10 can, when desired, be peeled away from the wound and will generally separate from the wound in a single, intact dressing.
- residual chitosan gel may remain, and this can be removed using saline or water with gentle abrasion and a gauze dressing.
- Chitosan is biodegradable within the body and is broken down into glucosamine, a benign substance. Still, it is desirable in the case of temporary dressings, that efforts should be made to remove all portions of chitosan from the wound at the time of definitive repair.
- tissue dressing assembly 10 and 10 principally in the setting of stanching blood and/or fluid loss at a wound site.
- Other indications have been mentioned, and certain of these and other additional indications now will be described in greater detail.
- a supple hydrophilic polymeric sponge structure of which the chitosan matrix is but one example, possesses can be incorporated into dressing structures of diverse shapes, sizes, and configurations, to serve a diverse number of different indications.
- the shapes, sizes, and configurations that a given supple sponge structure e.g., the chitosan matrix 12 and 12'
- a given supple sponge structure e.g., the chitosan matrix 12 and 12'
- can take are not limited to the assembly 10 and 10' described, and can transform according to the demands of a particular indication.
- control of bleeding represents but one indication where preservation of a body fluid is tantamount to preserving health and perhaps life. Another such indication is in the treatment of burns.
- dressings are used to cover the burned area.
- the dressing keeps air off the area, reduces pain and protects blistered skin.
- the dressing also absorbs fluid as the tissue burn heals.
- Anti-microbial creams or ointments and/or moisturizers are also used to prevent drying and to ward off infection.
- a supple, densified hydrophilic polymer sponge structure (e.g., a chitosan matrix 12 of the type already described) can be used to treat a tissue burn region.
- the supple, densified hydrophilic polymer sponge structure e.g., a chitosan matrix 12 of the type already described.
- chitosan matrix 12 will absorb fluids and adhere to cover the burn region.
- the supple, densified hydrophilic polymer sponge structure e.g., the chitosan matrix 12
- a supple hydrophilic polymer sponge structure (with or without densification, e.g., a chitosan matrix 12 or 12' of the type already described) can be readily sized and configured for use as an antimicrobial gasket.
- the gasket can be sized and configured to be placed over an access site, e.g., an access site where an indwelling catheter and the like resides.
- the gasket can include a pass-through hole, which allows passage of the indwelling catheter through it. It should be appreciated that, in situations where there is only an incision or access site without a resident catheter, the anti-microbial component will not include the pass-through hole.
- the focus of treatment can also be after exposure to Staphylococcus aureus bacteria (staph) in general and/or to methicillin resistant Staphylococcus aureus (MRSA) in particular.
- MRSA is a type of Staphylococcus aureus bacteria that is resistant to antibiotics including methicillin, oxacillin, penicillin and amoxicillin. While 25% to 30% of the population is colonized with staph, approximately 1% is colonized with MRSA.
- Staph infections occur most frequently among persons in hospitals and healthcare facilities (such as nursing homes and dialysis centers) who have weakened immune systems. These healthcare- associated staph infections include surgical wound infections, urinary tract infections, bloodstream infections, and pneumonia. Staph and MRSA can also cause illness in persons outside of hospitals and healthcare facilities. MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are know as CA-MRSA infections. Staph or MRSA infections in the community are usually manifested as skin infections, such as pimples and boils, and occur in otherwise healthy people.
- the main mode of transmission of MRSA is via hands (especially health care workers' hands) which may become contaminated by contact with a) colonized or infected patients, b) colonized or infected body sites of the personnel themselves, or c) devices, items, or environmental surfaces contaminated with body fluids containing MRSA.
- recent reports show a link between tattooing and MRSA.
- attempts to treat the infections include the use of antimicrobial dressings made with silver or polyhexamethylene biguanide (PHMB) .
- PHMB polyhexamethylene biguanide
- a supple hydrophilic polymer sponge structure (with or without densification, e.g., a chitosan matrix 12 or 12' of the type already described) can be used to treat a site of infection by staph or MRSA.
- the supple hydrophilic polymer sponge structure e.g., chitosan matrix 12 or 12'
- the supple hydrophilic polymer sponge structure (e.g., the chitosan matrix 12 or 12') will absorb fluids and adhere to cover the infection site.
- the supple hydrophilic polymer sponge structure (e.g., the chitosan matrix 12 or 12') can also serve an anti-bacterial/anti-microbial protective barrier at the infection site.
- the excellent adhesive and mechanical properties of the densified supple matrix 12 make it eminently suitable for use in such applications on the extremity (epidermal use) and inside the body.
- Such applications would include short to medium term (0- 120 hour) control of infection and bleeding at catheter lead entry/exit points, at entry/exit points of biomedical devices for sampling and delivering application, and at severe injury sites when patient is in shock and unable to receive definitive surgical assistance.
- herpes simplex virus type 1 ( 11 HSVl) generally only infects those body tissues that lie above the waistline. It is HSVl that causes cold sores in the majority of cases. Cold sores (or lesions) are a type of facial sore that are found either on the lips or else on the skin in the area near the mouth. Some equivalent terminology used for cold sores is “fever blisters" and the medical term "recurrent herpes labialis”.
- HSV2 Herpes simplex virus type 2
- HSV2 Herpes simplex virus type 2
- HSVl Herpes simplex virus type 2
- sores also called lesions
- sores also appear on other parts of the body where the virus has entered through broken skin.
- a supple hydrophilic polymer sponge structure (with or without densification, e.g., a chitosan matrix 12 or 12' of the type already described) can be used as an antiviral patch assembly, for placement over a surface lesion of a type associated with HSVl or HSV2, or other forms of viral skin infections, such as molluscum contagiosum and warts.
- the excellent adhesive and mechanical properties of the supple, densified matrix 12 make it eminently- suitable for use in anti -viral applications on the extremity (epidermal use) and inside the body.
- the presence of the anti -viral patch formed from the matrix 12 can kill viral agents and promote healing in the lesion region.
- hemophilia is an inherited bleeding, or coagulation, disorder. People with hemophilia lack the ability to stop bleeding because of the low levels, or complete absence, of specific proteins, called "factors," in their blood that are necessary for clotting. The lack of clotting factor causes people with hemophilia to bleed for longer periods of time than people whose blood factor levels are normal or work properly.
- Idiopathic thrombocytopenic purpura is another blood coagulation disorder characterized by an abnormal decrease in the number of platelets in the blood. A decrease in platelets can result in easy- bruising, bleeding gums, and internal bleeding.
- a supple, densified matrix (e.g., the chitosan matrix 12) can be sized and configured to be applied as an interventional dressing, to intervene in a bleeding episode experience by a person having hemophilia or another coagulation disorder.
- the presence of the chitosan matrix 12 attracts red blood cell membranes, which fuse to chitosan matrix 12 upon contact.
- a clot can be formed very quickly and does not need the clotting proteins that are normally required for coagulation.
- the presence of the chitosan matrix 12 during a bleeding episode of a person having hemophilia or other coagulation disorder can accelerate the clotting process independent of the clotting cascade, which, in such people, is in some way compromised. For this reason, the presence of the chitosan matrix 12 on a dressing can be effective as an interventional tool for persons having a coagulation disorder like hemophilia.
- a supple densified matrix (e.g., the chitosan matrix 12 as previously described) can provide a topically- applied platform for the delivery of one or more therapeutic agents into the blood stream in a controlled release fashion.
- the therapeutic agents can be incorporated into the matrix structure, e.g., either before or after the freezing step, and before the drying and densification steps.
- the rate at which the therapeutic agents are released from the matrix structure can be controlled by the amount of densification. The more densified the hydrophilic polymer sponge structure is made to be, the slower will be the rate of release of the therapeutic agent incorporated into the structure.
- therapeutic agents that can be incorporated into a hydrophilic polymer sponge structure (e.g., the chitosan matrix 12) include, but are not limited to, drugs or medications, stem cells, antibodies, anti-microbials, anti-virals, collagens, genes, DNA, and other therapeutic agents,- hemostatic agents like fibrin; growth factors; and similar compounds.
- the beneficial properties of the supple, densified chitosan matrix 12 includes adherence to mucosal surfaces within the body, such as those lining the esophagus, gastro- intestinal tract, urinary tract, the mouth, nasal passages and airways, and lungs.
- This feature makes possible the incorporation of the chitosan matrix 12, e.g., in systems and devices directed to treating mucosal surfaces where the adhesive sealing characteristics, and/or accelerated clotting attributes, and/or antibacterial/anti-viral features of the chitosan matrix 12, as described, provides advantages.
- Such systems and methods can include the anastomosis of bowels and other gastro-intestinal surgical procedures, repairs to esophageal or stomach function, sealing about sutures, etc .
- a supple matrix structure (with or without densification, e.g., the chitosan matrix 12 or 12' described herein) can be shaped, sized, and configured for placement in association with tissue or bone in an oral cavity or an adjacent anatomic structure.
- the supple matrix structure can be used in various dental surgical procedures, e.g., a tooth extraction; or endodontic surgery; or periodontal surgery; or orthodontic treatment; or orthognathic surgery; or a biopsy; or gingival surgery; or osseous surgery; or scaling or root planning; or periodontal maintenance; or complete maxillary or mandibular denture; or complete or partial denture adjustment; or denture rebase or reline,- or soft tissue surgical extraction; or bony surgical extraction; or installation of an occlusal orthotic device or occlusal guard or occlusal adjustment; or oral surgery- involving jaw repair; treatment of cystic cavity defects in the jaw; or new bone growth or bone growth promotion; or any other surgical procedure or intervention affecting tissue in the oral cavity, anatomic structures in the oral cavity, or alveolar (jaw) bone.
- dental surgical procedures e.g., a tooth extraction; or endodontic surgery; or periodontal surgery; or orthodontic treatment; or orthognathic surgery; or a biopsy; or
- the supple matrix structure makes it possible to stanch, seal, or stabilize a site of tissue or bone injury, tissue or bone trauma, or tissue or bone surgery.
- the supple matrix structure can also form an anti -microbial or anti -viral barrier; and/or promote coagulation; and/or release a therapeutic agent; and/or treat a periodontal or bone surface; and/or combinations thereof.
- a supple matrix structure (with or without densification, e.g., the chitosan matrix 12 or 12' described herein) can be shaped, sized, and configured for placement in association with tissue in the anterior or posterior nasal cavity to stop bleeding when conditions affecting the nasal cavity and its anatomic structures arise, e.g.., epistaxis.
- the supple matrix structure makes it possible to stanch, seal, or stabilize bleeding in the nasal cavity.
- the supple matrix structure can also form an anti-microbial or anti -viral barrier; and/or promote coagulation; and/or release a therapeutic agent; and/or otherwise treat a nasal cavity condition; and/or combinations thereof.
- a supple matrix structure (preferably with densification, e.g., the chitosan matrix 12 descruibed herein) can be shaped, sized and configured for placement in association with tissue as a topical dressing for local management of bleeding wounds such as cuts, lacerations and abrasions, as well as for temporary- treatment of severely bleeding wounds such as surgical wounds (operative, postoperative, donor sites, dermatalogical , etc.) and traumatic injuries.
- the chitosan ' matrix 12 may be manufactured to any size, e.g., in a 3" x 5" rectangular size dressing. Additionally, the dressing may be cut to fit the specific wound area.
- the hemostatic mode of action at the wound site is directly related to: (i) strong wound sealing adhesive characteristics of the polycationic high specific surface area of the chitosan acetate sponge,- (ii) persistent strong and rapid polycationic binding (agglutination) of erythrocytes by the high specific surface area of the dressing to form a stable clot; and (iii) resistance of the dressing to dissolution under blood flow.
- a supple hydrophilic polymer sponge structure like the densified chitosan matrix 12 or the uncompressed chitosan matrix 12' , can be readily adapted for association with dressings or platforms of various sizes and configurations, such that a person of ordinary skill in the medical and/or surgical arts could adopt any supple hydrophilic polymer sponge structure, like the chitosan matrix 12 or 12' , to diverse indications on, in, or throughout the body.
- the described freeze-drying process provides a more homogenous matrix material that will further be useful in the above situations. Therefore, it should be apparent that above- described embodiments of this invention are merely descriptive of its principles and are not to be limited. The scope of this invention instead shall be determined from the scope of the following claims, including their equivalents .
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002663372A CA2663372A1 (en) | 2006-09-13 | 2007-09-13 | Supple tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan |
EP07838182A EP2061413A2 (en) | 2006-09-13 | 2007-09-13 | Supple tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan |
AU2007294765A AU2007294765A1 (en) | 2006-09-13 | 2007-09-13 | Supple tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan |
IL197588A IL197588A0 (en) | 2006-09-13 | 2009-03-12 | Hydrophillic polymer sponge structures and methods of producing the same |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/520,357 | 2006-09-13 | ||
US11/520,230 US20070066920A1 (en) | 2002-06-14 | 2006-09-13 | Supple tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan |
US11/520,230 | 2006-09-13 | ||
US11/520,357 US20070066924A1 (en) | 2004-12-23 | 2006-09-13 | Supple tissue dressing assemblies, systems, and methods formed from softened hydrophilic polymer sponge structures such as chitosan |
US11/541,991 US20070082023A1 (en) | 2002-06-14 | 2006-10-02 | Supple tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan |
US11/541,988 | 2006-10-02 | ||
US11/541,991 | 2006-10-02 | ||
US11/541,988 US20070083137A1 (en) | 2004-12-23 | 2006-10-02 | Supple tissue dressing assemblies, systems, and methods formed from softened hydrophilic polymer sponge structures such as chitosan |
US11/900,854 | 2007-09-13 | ||
US11/900,854 US20080128932A1 (en) | 2002-06-14 | 2007-09-13 | Supple tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008033462A2 true WO2008033462A2 (en) | 2008-03-20 |
WO2008033462A3 WO2008033462A3 (en) | 2008-08-21 |
Family
ID=56291012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/019927 WO2008033462A2 (en) | 2006-09-13 | 2007-09-13 | Supple tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2061413A2 (en) |
AU (1) | AU2007294765A1 (en) |
CA (1) | CA2663372A1 (en) |
WO (1) | WO2008033462A2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2279012A1 (en) * | 2008-05-02 | 2011-02-02 | Providence Health System-Oregon d/b/a Providence St. Vincent Medical Center | Wound dressing devices and methods |
US8920514B2 (en) | 2006-05-23 | 2014-12-30 | Providence Health System—Oregon | Systems and methods for introducing and applying a bandage structure within a body lumen or hollow body organ |
US10086105B2 (en) | 2008-10-06 | 2018-10-02 | Providence Health System—Oregon | Chitosan foam medical devices and methods |
CN113444200A (en) * | 2021-06-09 | 2021-09-28 | 广州丰歌生物科技有限责任公司 | Anti-freezing hydrogel and preparation method and application thereof |
US11406771B2 (en) | 2017-01-10 | 2022-08-09 | Boston Scientific Scimed, Inc. | Apparatuses and methods for delivering powdered agents |
US11433223B2 (en) | 2016-07-01 | 2022-09-06 | Boston Scientific Scimed, Inc. | Delivery devices and methods |
US11642281B2 (en) | 2018-10-02 | 2023-05-09 | Boston Scientific Scimed, Inc. | Endoscopic medical device for dispensing materials and method of use |
US11701448B2 (en) | 2018-01-12 | 2023-07-18 | Boston Scientific Scimed, Inc. | Powder for achieving hemostasis |
US11766546B2 (en) | 2018-01-31 | 2023-09-26 | Boston Scientific Scimed, Inc. | Apparatuses and methods for delivering powdered agents |
US11833539B2 (en) | 2018-10-02 | 2023-12-05 | Boston Scientific Scimed, Inc. | Fluidization devices and methods of use |
US11918780B2 (en) | 2019-12-03 | 2024-03-05 | Boston Scientific Scimed, Inc. | Agent administering medical device |
US11931003B2 (en) | 2019-12-03 | 2024-03-19 | Boston Scientific Scimed, Inc. | Medical devices for agent delivery and related methods of use |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8741335B2 (en) | 2002-06-14 | 2014-06-03 | Hemcon Medical Technologies, Inc. | Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as Chitosan |
US7482503B2 (en) | 2001-06-14 | 2009-01-27 | Providence Health System-Oregon | Wound dressing and method for controlling severe, life-threatening bleeding |
US9204957B2 (en) | 2005-03-17 | 2015-12-08 | Hemcon Medical Technologies, Inc. | Systems and methods for hemorrhage control and or tissue repair |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6406712B1 (en) * | 1991-10-09 | 2002-06-18 | Lectec Corporation | Aqueous gel and package for a wound dressing and method |
US6485667B1 (en) * | 1997-01-17 | 2002-11-26 | Rayonier Products And Financial Services Company | Process for making a soft, strong, absorbent material for use in absorbent articles |
US6552244B1 (en) * | 1999-01-09 | 2003-04-22 | Bristol-Myers Squibb Company | Multi-layered wound dressing |
-
2007
- 2007-09-13 EP EP07838182A patent/EP2061413A2/en not_active Withdrawn
- 2007-09-13 WO PCT/US2007/019927 patent/WO2008033462A2/en active Search and Examination
- 2007-09-13 AU AU2007294765A patent/AU2007294765A1/en not_active Abandoned
- 2007-09-13 CA CA002663372A patent/CA2663372A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6406712B1 (en) * | 1991-10-09 | 2002-06-18 | Lectec Corporation | Aqueous gel and package for a wound dressing and method |
US6485667B1 (en) * | 1997-01-17 | 2002-11-26 | Rayonier Products And Financial Services Company | Process for making a soft, strong, absorbent material for use in absorbent articles |
US6552244B1 (en) * | 1999-01-09 | 2003-04-22 | Bristol-Myers Squibb Company | Multi-layered wound dressing |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8920514B2 (en) | 2006-05-23 | 2014-12-30 | Providence Health System—Oregon | Systems and methods for introducing and applying a bandage structure within a body lumen or hollow body organ |
JP2011523567A (en) * | 2008-05-02 | 2011-08-18 | プロビデンス ヘルス システム−オレゴン ディー/ビー/エー プロビデンス セント ビンセント メディカル センター | Wound dressing device and method |
EP2279012A4 (en) * | 2008-05-02 | 2013-05-29 | Providence Health Sys Oregon | Wound dressing devices and methods |
KR101548766B1 (en) | 2008-05-02 | 2015-08-31 | 프로비던스 헬스 앤드 서비시즈, 오레곤 | Wound dressing devices and methods |
EP2279012A1 (en) * | 2008-05-02 | 2011-02-02 | Providence Health System-Oregon d/b/a Providence St. Vincent Medical Center | Wound dressing devices and methods |
US10086105B2 (en) | 2008-10-06 | 2018-10-02 | Providence Health System—Oregon | Chitosan foam medical devices and methods |
US11433223B2 (en) | 2016-07-01 | 2022-09-06 | Boston Scientific Scimed, Inc. | Delivery devices and methods |
US11406771B2 (en) | 2017-01-10 | 2022-08-09 | Boston Scientific Scimed, Inc. | Apparatuses and methods for delivering powdered agents |
US11701448B2 (en) | 2018-01-12 | 2023-07-18 | Boston Scientific Scimed, Inc. | Powder for achieving hemostasis |
US11766546B2 (en) | 2018-01-31 | 2023-09-26 | Boston Scientific Scimed, Inc. | Apparatuses and methods for delivering powdered agents |
US11642281B2 (en) | 2018-10-02 | 2023-05-09 | Boston Scientific Scimed, Inc. | Endoscopic medical device for dispensing materials and method of use |
US11833539B2 (en) | 2018-10-02 | 2023-12-05 | Boston Scientific Scimed, Inc. | Fluidization devices and methods of use |
US11918780B2 (en) | 2019-12-03 | 2024-03-05 | Boston Scientific Scimed, Inc. | Agent administering medical device |
US11931003B2 (en) | 2019-12-03 | 2024-03-19 | Boston Scientific Scimed, Inc. | Medical devices for agent delivery and related methods of use |
CN113444200A (en) * | 2021-06-09 | 2021-09-28 | 广州丰歌生物科技有限责任公司 | Anti-freezing hydrogel and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
AU2007294765A1 (en) | 2008-03-20 |
CA2663372A1 (en) | 2008-03-20 |
EP2061413A2 (en) | 2009-05-27 |
WO2008033462A3 (en) | 2008-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070066924A1 (en) | Supple tissue dressing assemblies, systems, and methods formed from softened hydrophilic polymer sponge structures such as chitosan | |
US20070083137A1 (en) | Supple tissue dressing assemblies, systems, and methods formed from softened hydrophilic polymer sponge structures such as chitosan | |
US20070066920A1 (en) | Supple tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan | |
US20070082023A1 (en) | Supple tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan | |
WO2008033462A2 (en) | Supple tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan | |
KR101105081B1 (en) | Tissue Dressing Assemblies, Systems, and Methods Formed from Hydrophilic Polymer Sponge Structures such as Chitosan | |
US20050147656A1 (en) | Tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan | |
US7897832B2 (en) | Compositions, assemblies, and methods applied during or after a dental procedure to ameliorate fluid loss and/or promote healing, using a hydrophilic polymer sponge structure such as chitosan | |
JP4332030B2 (en) | Wound dressing and method for controlling severe and life-threatening bleeding | |
JP5931339B2 (en) | Biocompatible hemostasis, adhesion prevention, fusion promotion, surgically sealable modified starch material | |
US8269058B2 (en) | Absorbable tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan | |
US7371403B2 (en) | Wound dressing and method for controlling severe, life-threatening bleeding | |
ZA200605125B (en) | Tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chistosan | |
JP2011509932A5 (en) | ||
EP2173293A1 (en) | Absorbable tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chistosan | |
KR20060134346A (en) | Microporous dressing material of chitosan complex and production method | |
IL184044A (en) | Antimicrobial barriers including a chitosan biomaterial and methods for the manufacture thereof | |
US20080128932A1 (en) | Supple tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07838182 Country of ref document: EP Kind code of ref document: A2 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2663372 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007294765 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007838182 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2007294765 Country of ref document: AU Date of ref document: 20070913 Kind code of ref document: A |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |